StockNews.com initiated coverage on shares of LiqTech International (NASDAQ:LIQT – Get Free Report) in a research note issued on Sunday. The firm set a “sell” rating on the stock.
Separately, Ascendiant Capital Markets assumed coverage on LiqTech International in a report on Monday, February 26th. They set a “buy” rating and a $5.15 price target on the stock.
Get Our Latest Research Report on LIQT
LiqTech International Stock Performance
LiqTech International (NASDAQ:LIQT – Get Free Report) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.41) earnings per share for the quarter. LiqTech International had a negative return on equity of 48.20% and a negative net margin of 47.02%. The company had revenue of $4.24 million for the quarter.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in LiqTech International stock. Mesirow Financial Investment Management Inc. bought a new position in LiqTech International, Inc. (NASDAQ:LIQT – Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 14,903 shares of the company’s stock, valued at approximately $46,000. Mesirow Financial Investment Management Inc. owned 0.26% of LiqTech International at the end of the most recent reporting period. 35.06% of the stock is currently owned by institutional investors.
About LiqTech International
LiqTech International, Inc, a clean technology company, designs, develops, produces, markets, and sells automated filtering systems, ceramic silicon carbide liquid applications, and diesel particulate air filters in the United States, Canada, Europe, Asia, and South America. The company operates through Water, Ceramics, and Plastics segments.
Further Reading
- Five stocks we like better than LiqTech International
- How to Calculate Stock Profit
- McDonald’s Stock: Balancing Value and Innovation
- What is the FTSE 100 index?
- MarketBeat Week in Review – 6/17 – 6/21
- Using the MarketBeat Dividend Yield Calculator
- Sarepta Therapeutics Stock Soars on FDA Approval
Receive News & Ratings for LiqTech International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LiqTech International and related companies with MarketBeat.com's FREE daily email newsletter.